At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 618 enrolled
Drug / intervention
Ruxolitinib cream +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
In Brief
A Phase 3 clinical trial evaluating Ruxolitinib cream and Vehicle cream for Atopic Dermatitis. Completed, enrolled 618 participants across 66 sites in 7 countries.
Detailed Summary
The purpose of this study is to assess the efficacy of ruxolitinib cream in adolescents and adults with atopic dermatitis (AD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesBulgaria, Canada, Czechia, Germany, Poland, Spain, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedNov 2018
Enrollment StartDec 2018
Primary CompletionNov 2019
Study CompletionNov 2020
TodayJul 2026
First PostedNov 19, 2018
Enrollment StartDec 20, 2018
Primary CompletionNov 18, 2019
Study CompletionNov 9, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 7.6 years ago
Interventions
Ruxolitinib creamdrug
Ruxolitinib 0.75% or 1.5% cream.
Vehicle creamdrug
Ruxolitinib matching vehicle cream.